iRhythm gets $10 million for cardiac monitoring

By: Brian Dolan | May 18, 2010        

Tags: | | | | | | |  |

iRhythm Zio PatchSt. Jude Medical and iRhythm Technologies have inked a deal to co-market iRhythm’s Zio Patch, an wearable, single-use continuous ambulatory cardiac rhythm monitor. The Zio patch recently received 510(k) clearance from the FDA and is prepping for a commercial launch in the US, which is where the company’s new cash infusion comes in:

iRhythm also announced a $10 million round of financing that was led by St. Jude Medical with participation from previous investors Mohr Davidow Ventures and Synergy Life Science Partners. iRhythm has now raised close to $30 million in total funding.

“As a global leader in the treatment of cardiovascular disorders, St. Jude Medical has developed many important innovations to improve patient care,” said Bill Willis, President and Chief Executive Officer of iRhythm. “We’re pleased to begin this partnership which aims to identify patients with arrhythmias earlier, ultimately improving outcomes.”

“With their breakthrough technology, iRhythm aims to simplify the complexities of cardiac rhythm monitoring in order to streamline the referral process and promote timely access to specialty care and treatment,” said Michael Rousseau, Group President of St. Jude Medical. “Through this partnership with iRhythm, St. Jude Medical will provide physicians a way to more easily and cost-effectively triage and diagnose patients potentially experiencing arrhythmias.”

For more, read the press release here

  • David Albert, MD

    I don’t think the Zio patch is wireless. It is a 1-2 week continuous single lead ecg recorder which you mail back to iRhythm. It is a long duration, single lead holter monitor.

  • Donald Jones

    “Not all wireless health is mobile and not all mobile health is wireless” – but either way most of it is good news for consumers.

  • Paul Sonnier

    With all due respect, the iRhythm product does not qualify as mobile health – at least not as the term is defined on MobiHealthNews’ About page: “MobiHealthNews chronicles the healthcare sector’s adoption of mobile technology: A convergence of two industries that is shaping the future of how healthcare is delivered to the patient on-the-go, at home and at their place of care.”

    While not explicitly stated, the “two industries” implies – to me, at least – the telecommunications/wireless/mobile carriers (aka “mobile industry”) and the healthcare industry. In the case of iRhythm, the convergence is between what two industries—the medical device industry and healthcare industry?

    Sorry to appear petty, but I abhor ambiguity and if we’re dedicating so much time, energy, and resources to covering and trying to accelerate an “mHealth revolution” – more appropriate would be “wireless health” revolution – shouldn’t we avoid muddling things via this kind of scope creep?

    Moreover, the aforementioned definition provided by MobiHealthNews excludes the consumer, or, for lack of a better catch-all term, the consumer health industry. As I’ve purposed my Wireless Health group on LinkedIn, I explicitly include the consumer in the scope of discussion as follows: “The Wireless Health group’s central discussion forum is dedicated to advancing knowledge and building relationships between professionals interested in the convergence of wireless technology with the continuum of clinical healthcare (preventive, chronic, and acute) and consumer health (physical fitness, wellness, and elderly monitoring).”

    Best regards,
    Paul Sonnier

    Founder, Wireless Health group on LinkedIn (
    Co-Chair, Healthcare Communications SIG at CommNexus San Diego

  • Brian Dolan

    Hi Paul,

    Our more recent coverage of iRhythm may help: